JNJ

Sponsored Post

The emerging golden era of neuroscience

Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.

Health IT

CONVERGE product demonstration: Janssen Healthcare Innovation

One theory behind improving patient adherence is it’s a question of memory and helping people stay better organized. For people who may be taking several medications at once, missing one or two medication times can lessen the effect of the drug, or negatively impact the person’s health. Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Healthcare […]

News

FDA turns down higher dosage for HIV drug Prezista

An application for a higher dosage of an FDA-approved HIV drug from Janssen Pharmaceuticals has been turned down by the U.S. Food and Drug Administration, according to a company statement. The complete response letter was for an 800 milligram dose of Prezista, a protease inhibitor. The Titusville, New Jersey company, the Pharmaceutical Division of Johnson […]

Devices & Diagnostics

J&J and Medtronic have contrasting acquisition strategies. Can both win?

Johnson and Johnson’s (NYSE:JNJ) CEO Alex Gorsky is apparently shopping around for medical device companies to boost sagging sales in its Cardiovascular Division. A Bloomberg story highlights how some analysts believe companies like St. Jude Medical and Edwards Lifesciences could be good acquisition targets.  J&J’s strategy of growing through acquisitions appears to contrast with the […]

Pharma

Johnson & Johnson’s Q1 performance paints a mixed picture

Despite encouraging sales performance in the first quarter for recently approved oncology drugs, Johnson & Johnson (NYSE:JNJ) continues to be vexed by manufacturing problems. That, coupled with new questions over its incoming CEO, paint a mixed picture for how 2012 will shake out for the pharmaceutical and medical device giant. A consent decree from the […]